CRA developed economic analyses to determine damages in a patent infringement case involving a pharmaceutical product used for the treatment of congestive heart failure and skinny labeling by a generic competitor. CRA provided an initial report on economic damages calculating lost profits and reasonable royalties as well as deposition and trial testimony.
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...